U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07067255) titled 'Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer' on July 05.
Brief Summary: This is a multicenter, open-label Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of sequentially administered CD146-targeted and GPC3-targeted CAR-T cell therapy in patients with advanced relapsed or refractory ovarian cancer. Eligible patients will undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by an infusion of autologous CD146-directed CAR-T cells (Arm A) and a subsequent infusion of autologous GPC3-directed CAR-T cells (Arm B). The Phase 1 portion will assess safety, t...